EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

Lilian T Gien iD, Zihe Song, Andrew Poklepovic iD, Eric A Collisson iD, James A Zwiebel iD, Robert J Gray iD, Victoria Wang, Lisa M McShane iD, Larry V Rubinstein iD, David R Patton iD, P Mickey Williams, Stanley R Hamilton iD und 7 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po-24-00514 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Lilian T Gien und 18 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Sunitinib, Proto-Oncogene Proteins c-kit, Mutation, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The NCI-MATCH study is a tumor-agnostic platform trial enrolling patients to targeted therapies on the basis of genomic alterations. Subprotocol V investigated sunitinib in patients with tumors harboring c - KIT mutations. METHODS EAY131-V, is an open-label, single-arm, phase II study. Eligible patients had malignancies containing somatic c-KIT mutation on exons 9, 11, 13, or 14. Exclusions were mutations on exons 17 and 18, gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. Patients received sunitinib 50 mg orally once daily for 4 weeks with 2-week rest per cycle, until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR); secondary end points were progression-free survival (PFS) at 6 months, PFS, overall survival, and toxicities. RESULTS Between November 1, 2016, and May 21, 2020, 10 patients were enrolled and nine were eligible and started treatment. The median age was 62 years (range, 30-76), 77.8% received two previous lines of systemic therapy, and 22.2% received >3 lines. The most common histology was melanoma (44%) and then squamous cell carcinoma of the lung or thymus (33%). There were two partial responses with an ORR of 22.2% (90% CI, 4.1 to 55) and stable disease in 44%. All patients demonstrated tumor shrinkage of target lesions. The estimated 6-month PFS was 33.3% (90% CI, 15.4 to 72.4). Grade 3-4 toxicities occurred in five patients (55.6%). This arm was closed in 2022 on the basis of low accrual. Prevalence of eligible c-KIT mutations after screening 5,540 patients was 0.45%. CONCLUSION Sunitinib for c-KIT mutations did not meet the primary end point, but in this small sample size, a potential signal cannot be ruled out. Rate of eligible c-KIT mutations was low, affecting accrual to this arm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibProto-Oncogene Proteins c-kitMutationAntineoplastic AgentsHumansMiddle AgedMaleFemaleAdultAgedNeoplasms

Substanzen

SunitinibProto-Oncogene Proteins c-kitAntineoplastic AgentsKIT protein, human

Autor:innen und Institutionen

  • Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.
  • Virginia Commonwealth University/Massey Cancer Center, Richmond, VA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
  • Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

ORCID-Profile: Lilian T Gien, Andrew Poklepovic, Eric A Collisson, James A Zwiebel, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David R Patton, Stanley R Hamilton, James V Tricoli, Barbara A Conley, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty

Förderung

  • NCI NIH HHS

Zitieren

APA

Gien, L. T., Song, Z., Poklepovic, A., Collisson, E. A., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D. R., Williams, P. M., Hamilton, S. R., Tricoli, J. V., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2024). Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V. JCO Precision Oncology. https://doi.org/10.1200/po-24-00514

Vancouver

Gien LT, Song Z, Poklepovic A, Collisson EA, Zwiebel JA, Gray RJ, et al. Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V. JCO Precision Oncology. 2024. doi:10.1200/po-24-00514

BibTeX
@article{Gien2024,
  author = {Gien, Lilian T and Song, Zihe and Poklepovic, Andrew and Collisson, Eric A and Zwiebel, James A and Gray, Robert J and Wang, Victoria and McShane, Lisa M and Rubinstein, Larry V and Patton, David R and Williams, P Mickey and Hamilton, Stanley R and Tricoli, James V and Conley, Barbara A and Arteaga, Carlos L and Harris, Lyndsay N and O'Dwyer, Peter J and Chen, Alice P and Flaherty, Keith T},
  title = {Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po-24-00514}
}
Kostenlos starten →